Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

54
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
54
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.8K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

22
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
22
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

38
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
38

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular Disease Update: Peripheral Artery Disease.

FP essentials·2025
Same author

Cardiovascular Disease Update: Coronary Artery Disease Risk Assessment and Noninvasive Testing.

FP essentials·2025
Same author

Cardiovascular Disease Update: Medical Management of Chronic Coronary Disease.

FP essentials·2025
Same author

Mindfulness-Enhanced Parenting Programs Improve the Psychosocial Outcomes of Children up to 18 Years and Their Parents.

American family physician·2024
Same author

Combined Oral Contraceptives for Primary Dysmenorrhea.

American family physician·2024
Same author

Aspirin Use and the Risk of Mortality in Patients With Hypertension.

American family physician·2023
Same journal

Skin Cancer: Management of Cutaneous Melanoma.

FP essentials·2026
Same journal

Skin Cancer: Management of Actinic Keratoses and Keratinocyte Carcinomas.

FP essentials·2026
Same journal

Skin Cancer: Diagnosis.

FP essentials·2026
Same journal

Skin Cancer: Screening and Prevention.

FP essentials·2026
Same journal

Skin Cancer.

FP essentials·2026
Same journal

Obesity Management: Surgical Interventions.

FP essentials·2026
See all related articles

Related Experiment Video

Updated: Sep 10, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K

Cardiovascular Disease Update: Heart Failure Update.

Kevin A Bobeck1, Anthony M Recidoro2, Joseph M Sapoval3

  • 1Walter Reed National Military Medical Center, Bethesda, MD.

FP Essentials
|August 19, 2025
PubMed
Summary
This summary is machine-generated.

Heart failure (HF) management involves early diagnosis and staging. Effective treatments for reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) improve patient outcomes and reduce hospitalizations.

More Related Videos

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.8K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

Related Experiment Videos

Last Updated: Sep 10, 2025

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
14:24

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

Published on: January 21, 2018

11.8K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Heart failure (HF) is a prevalent condition where the heart cannot pump blood effectively, impacting millions globally.
  • Increasing prevalence, hospitalizations, and mortality rates highlight the urgent need for effective HF management strategies.
  • HF classification includes HF with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF), guiding treatment approaches.

Purpose of the Study:

  • To review current diagnostic and therapeutic strategies for heart failure.
  • To emphasize the importance of early diagnosis and staging in managing HF.
  • To discuss the role of pharmacologic and non-pharmacologic interventions in improving HF patient outcomes.

Main Methods:

  • Review of guideline-directed medical therapies for HFrEF.
  • Analysis of comorbidity management strategies, including obesity treatment in HFpEF.
  • Inclusion of advanced therapies, cardiac rehabilitation, and supportive interventions.

Main Results:

  • Guideline-directed medical therapy significantly reduces morbidity, mortality, and hospitalizations in HFrEF patients.
  • Management of comorbidities, such as obesity with GLP-1 receptor agonists in HFpEF, improves outcomes.
  • Comprehensive care including advanced therapies and supportive interventions enhances quality of life.

Conclusions:

  • Early diagnosis and staging are crucial for effective heart failure management.
  • Multifaceted treatment strategies, encompassing guideline-directed medical therapy, comorbidity management, and supportive care, are essential for reducing HF progression and improving survival.
  • Continued focus on both pharmacologic and non-pharmacologic approaches is vital for optimizing patient outcomes in heart failure.